Therefore, we hypothesize that patients exhibiting loss of PTEN tumor suppressor activity may be more likely to benefit from a combined therapeutic approach involving anti-angiogenesis therapy with immunotherapy, as is currently being investigated in a phase 2 clinical trial enrolling untreated MBM patients (NCT03175432). This evidence concerns the gene PTEN and neoplasm.